» Articles » PMID: 20220849

B-cell-derived Lymphotoxin Promotes Castration-resistant Prostate Cancer

Overview
Journal Nature
Specialty Science
Date 2010 Mar 12
PMID 20220849
Citations 344
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer (CaP) progresses from prostatic intraepithelial neoplasia through locally invasive adenocarcinoma to castration-resistant metastatic carcinoma. Although radical prostatectomy, radiation and androgen ablation are effective therapies for androgen-dependent CaP, metastatic castration-resistant CaP is a major complication with high mortality. Androgens stimulate growth and survival of prostate epithelium and early CaP. Although most patients initially respond to androgen ablation, many develop castration-resistant CaP within 12-18 months. Despite extensive studies, the mechanisms underlying the emergence of castration-resistant CaP remain poorly understood and their elucidation is critical for developing improved therapies. Curiously, castration-resistant CaP remains androgen-receptor dependent, and potent androgen-receptor antagonists induce tumour regression in castrated mice. The role of inflammation in castration-resistant CaP has not been addressed, although it was reported that intrinsic NF-kappaB activation supports its growth. Inflammation is a localized protective reaction to injury or infection, but it also has a pathogenic role in many diseases, including cancer. Whereas acute inflammation is critical for host defence, chronic inflammation contributes to tumorigenesis and metastatic progression. The inflammation-responsive IkappaB kinase (IKK)-beta and its target NF-kappaB have important tumour-promoting functions within malignant cells and inflammatory cells. The latter, including macrophages and lymphocytes, are important elements of the tumour microenvironment, but the mechanisms underlying their recruitment remain obscure, although they are thought to depend on chemokine and cytokine production. We found that CaP progression is associated with inflammatory infiltration and activation of IKK-alpha, which stimulates metastasis by an NF-kappaB-independent, cell autonomous mechanism. Here we show that androgen ablation causes infiltration of regressing androgen-dependent tumours with leukocytes, including B cells, in which IKK-beta activation results in production of cytokines that activate IKK-alpha and STAT3 in CaP cells to enhance hormone-free survival.

Citing Articles

Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.

De Domenico P, Gagliardi F, Roncelli F, Snider S, Mortini P J Neurooncol. 2025; .

PMID: 40080248 DOI: 10.1007/s11060-025-04989-z.


NF-κB signaling and the tumor microenvironment in osteosarcoma: implications for immune evasion and therapeutic resistance.

Shi S, Ou X, Liu C, Li R, Zheng Q, Hu L Front Immunol. 2025; 16:1518664.

PMID: 39949765 PMC: 11821961. DOI: 10.3389/fimmu.2025.1518664.


Systematic evaluation of intratumoral and peripheral BCR repertoires in three cancers.

Krasik S, Bryushkova E, Sharonov G, Myalik D, Shurganova E, Komarov D Elife. 2025; 13.

PMID: 39831798 PMC: 11745494. DOI: 10.7554/eLife.89506.


B cells enhance IL-1 beta driven invasiveness in triple negative breast cancer.

Toney N, Opdenaker L, Frerichs L, Modarai S, Ma A, Archinal H Sci Rep. 2025; 15(1):2211.

PMID: 39820772 PMC: 11739487. DOI: 10.1038/s41598-025-86064-1.


B cells enhance IL-1 beta driven invasiveness in triple-negative breast cancer.

Toney N, Opdenaker L, Frerichs L, Modarai S, Ma A, Archinal H Res Sq. 2025; .

PMID: 39801513 PMC: 11722549. DOI: 10.21203/rs.3.rs-5153341/v1.


References
1.
Balkwill F, Charles K, Mantovani A . Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005; 7(3):211-7. DOI: 10.1016/j.ccr.2005.02.013. View

2.
de Visser K, Korets L, Coussens L . De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005; 7(5):411-23. DOI: 10.1016/j.ccr.2005.04.014. View

3.
Gulley J, Figg W, Dahut W . Treatment options for androgen-independent prostate cancer. Clin Adv Hematol Oncol. 2005; 1(1):49-57. View

4.
Watson P, Ellwood-Yen K, King J, Wongvipat J, LeBeau M, Sawyers C . Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 2005; 65(24):11565-71. DOI: 10.1158/0008-5472.CAN-05-3441. View

5.
Karin M, Lawrence T, Nizet V . Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006; 124(4):823-35. DOI: 10.1016/j.cell.2006.02.016. View